Skip to main content

Diamics Supplies Cervical Cancer-Screening System to Beijing Hospital in $22M Deal

NEW YORK (GenomeWeb News) — Diamics will supply its molecular-based cancer-diagnostics systems and cervical cancer tools to a Beijing hospital for three years in exchange for at least $22 million, the company said today.
 
Diamics’ C-Map cervical cancer screening system, which is in clinical trials in the US, uses antibodies to identify cell colonies showing dysregulated growth, which could help identify cervical lesions. 
 
The Novata, Calif.-based company said the deal is part of a Chinese government-led initiative to improve detection of cervical cancer.
 
It said its cervical sample collection tool received 510(k) clearance from the US Food and Drug Administration last week.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.